Locally advanced pancreatic cancer – novel therapeutic strategies

Pancreatic cancer still remains a devastating disease due to its early invasion and metastasis formation. More than 80 % of patients are initially diagnosed with advanced, incurable disease. Until recently, palliative chemotherapy was the only therapeutic option. At the symposium, internationally recognized experts will portray and discuss novel therapeutic strategies for locally advanced, non-metastatic disease that are currently emerging.

The focus of the symposium is on advanced pancreatic cancer and its management. Neoadjuvant pretreatment of borderline resectable tumors has lead to secondary resectability in up to 30 %. In palliation several techniques as focussed radiation therapy by cyberknife and irreversible electroporation have recently emerged and the current State of the Art and evidence is presented in this meeting by internationally reknown experts in the field.

Hier finden Sie weitere Informationen zum Programm und zur Anmeldung.

Introduction
Prof. Dr. Tobias Keck, Klinik für Chirurgie, UKSH, Campus Lübeck

Cyberknife radiation therapy of locally advanced pancreatic cancer
Prof. Dr. med. Anand Mahadevan, Department of Radiation Oncology, Geisinger / Health Systems, Danville, USA

Irreversible Electroporation (IRE) of locally advanced pancreatic cancer
Prof. Dr. med. Robert C.G. Martin, Department of Surgery, University of Louisville / School of Medicine, Louisville, USA

Neoadjuvant chemotherapy of locally advanced pancreatic cancer
PD Dr. med. Thorsten Oliver Götze, Institut für Klinisch-Onkologische Forschung, Krankenhaus Nordwest GmbH, Frankfurt am Main

Neoadjuvant radiochemotherapy of locally advanced pancreatic cancer
Prof. Dr. med. Thomas Brunner, Klinik für Strahlenheilkunde, Universitätsklinikum Freiburg

Surgical therapy of locally advanced pancreatic cancer
Prof. Dr. Tobias Keck

Round table discussion